14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bronchiolitis obliterans (BO) is a rare, chronic form of obstructive lung disease, often initiated with injury of the bronchiolar epithelium followed by an inflammatory response and progressive fibrosis of small airways resulting in nonuniform luminal obliteration or narrowing. The term BO comprises a group of diseases with different underlying etiologies, courses, and characteristics. Among the better recognized inciting stimuli leading to BO are airway pathogens such as adenovirus and mycoplasma, which, in a small percentage of infected children, will result in progressive fixed airflow obstruction, an entity referred to as postinfectious bronchiolitis obliterans (PIBO). The present knowledge on BO in general is reasonably well developed, in part because of the relatively high incidence in patients who have undergone lung transplantation or bone marrow transplant recipients who have had graft-versus-host disease in the posttransplant period. The cellular and molecular pathways involved in PIBO, while assumed to be similar, have not been adequately elucidated. Since 2016, an international consortium of experts with an interest in PIBO assembles on a regular basis in Geisenheim, Germany, to discuss key areas in PIBO which include diagnostic workup, treatment strategies, and research fields.

          Related collections

          Most cited references110

          • Record: found
          • Abstract: not found
          • Article: not found

          The forced oscillation technique in clinical practice: methodology, recommendations and future developments

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Biomarkers for severe eosinophilic asthma.

            The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma. Based on the available evidence and combined with clinical judgement, a baseline blood eosinophil threshold of 150 cells/μL or greater or a historical blood eosinophil threshold of 300 cells/μL or greater will allow selection of patients with severe eosinophilic asthma who are most likely to achieve clinically significant reductions in the rate of exacerbations with mepolizumab treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma.

              There are few data in asthma relating airway physiology, inflammation and remodelling and the relative effects of inhaled corticosteroid (ICS) treatment on these parameters. A study of the relationships between spirometric indices, airway inflammation, airway remodelling, and bronchial hyperreactivity (BHR) before and after treatment with high dose inhaled fluticasone propionate (FP 750 microg bd) was performed in a group of patients with relatively mild but symptomatic asthma. A double blind, randomised, placebo controlled, parallel group study of inhaled FP was performed in 35 asthmatic patients. Bronchoalveolar lavage (BAL) and airway biopsy studies were carried out at baseline and after 3 and 12 months of treatment. Twenty two normal healthy non-asthmatic subjects acted as controls. BAL fluid eosinophils, mast cells, and epithelial cells were significantly higher in asthmatic patients than in controls at baseline (p<0.01). Subepithelial reticular basement membrane (rbm) thickness was variable, but overall was increased in asthmatic patients compared with controls (p<0.01). Multiple regression analysis explained 40% of the variability in BHR, 21% related to rbm thickness, 11% to BAL epithelial cells, and 8% to BAL eosinophils. The longitudinal data corroborated the cross sectional model. Forced expiratory volume in 1 second improved after 3 months of treatment with FP with no further improvement at 12 months. PD(20) improved throughout the study. BAL inflammatory cells decreased following 3 months of treatment with no further improvement at 12 months (p<0.05 v placebo). Rbm thickness decreased in the FP group, but only after 12 months of treatment (mean change -1.9, 95% CI -3 to -0.7 microm; p<0.01 v. baseline, p<0.05 v. placebo). A third of the improvement in BHR with FP was associated with early changes in inflammation, but the more progressive and larger improvement was associated with the later improvement in airway remodelling. Physiology, airway inflammation and remodelling in asthma are interrelated and improve with ICS. Changes are not temporally concordant, with prolonged treatment necessary for maximal benefit in remodelling and PD(20). Determining the appropriate dose of inhaled steroids only by reference to symptoms and lung function, as specified in current international guidelines, and even against indices of inflammation may be over simplistic. The results of this study support the need for early and long term intervention with ICS, even in patients with relatively mild asthma.
                Bookmark

                Author and article information

                Contributors
                Journal
                Can Respir J
                Can. Respir. J
                CRJ
                Canadian Respiratory Journal
                Hindawi
                1198-2241
                1916-7245
                2020
                30 January 2020
                : 2020
                : 5852827
                Affiliations
                1Division for Allergy, Pneumology and Cystic Fibrosis, Department for Children and Adolescence, Goethe-University, Frankfurt/Main, Germany
                2Department of Paediatric Pneumology, Children's Hospital, Ruhr University of Bochum, Bochum, Germany
                3Radiology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
                4Boston Children's Hospital, Harvard Medical School, Boston, USA
                5Division of Pathology and Laboratory Medicine, Phoenix Children's Hospital, Phoenix, USA
                6Department of Pediatric Pneumology, Dr. von Hauner Children's Hospital, LMU Munich, German Center for Lung Research (DZL), Munich, Germany
                7Division of Pediatric Pulmonary Medicine, Allergy and Immunology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, USA
                8University of Ulm Medical Centre, Clinic for Child and Adolescent Psychiatry/Psychotherapy, Ulm, Germany
                9Division of Respiratory Medicine, Department of Pediatrics, University Children's Hospital of Bern, University of Bern, Bern, Switzerland
                10Department of General Pediatrics, University Children's Hospital, Düsseldorf, Germany
                11Department of Pulmonary Medicine, University Hospital Basel, Basel, Switzerland
                Author notes

                Academic Editor: Motoshi Takao

                Author information
                https://orcid.org/0000-0003-2972-649X
                https://orcid.org/0000-0002-3566-9690
                https://orcid.org/0000-0003-1204-0627
                Article
                10.1155/2020/5852827
                7013295
                32076469
                bae4778a-0d4e-4534-a3f4-af4ee551b494
                Copyright © 2020 Silvija-Pera Jerkic et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 27 August 2019
                : 29 November 2019
                : 27 December 2019
                Funding
                Funded by: University of Pennsylvania
                Award ID: MDBR-16-116-BO
                Categories
                Review Article

                Comments

                Comment on this article